Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus

Fangfang Dong, Dandan Li, Dan Wen, Suhua Li, Chaoyue Zhao, Yue Qi, Rohit Jangra, Cuiping Wu, Dequan Xia, Xing Zhang, Fei Deng, Kartik Chandran, Zhen Zou, Fei Yuan, Aihua Zheng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.

Original languageEnglish (US)
Article number5
Journalnpj Vaccines
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Vesicular Stomatitis
Thrombocytopenia
Phlebovirus
Fever
Vaccines
Viruses
Glycoproteins
Active Immunotherapy
Ticks
Neutralizing Antibodies
Antiviral Agents
Immunity

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. / Dong, Fangfang; Li, Dandan; Wen, Dan; Li, Suhua; Zhao, Chaoyue; Qi, Yue; Jangra, Rohit; Wu, Cuiping; Xia, Dequan; Zhang, Xing; Deng, Fei; Chandran, Kartik; Zou, Zhen; Yuan, Fei; Zheng, Aihua.

In: npj Vaccines, Vol. 4, No. 1, 5, 01.12.2019.

Research output: Contribution to journalArticle

Dong, F, Li, D, Wen, D, Li, S, Zhao, C, Qi, Y, Jangra, R, Wu, C, Xia, D, Zhang, X, Deng, F, Chandran, K, Zou, Z, Yuan, F & Zheng, A 2019, 'Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus', npj Vaccines, vol. 4, no. 1, 5. https://doi.org/10.1038/s41541-018-0096-y
Dong, Fangfang ; Li, Dandan ; Wen, Dan ; Li, Suhua ; Zhao, Chaoyue ; Qi, Yue ; Jangra, Rohit ; Wu, Cuiping ; Xia, Dequan ; Zhang, Xing ; Deng, Fei ; Chandran, Kartik ; Zou, Zhen ; Yuan, Fei ; Zheng, Aihua. / Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. In: npj Vaccines. 2019 ; Vol. 4, No. 1.
@article{365de33cd6024b78993aa46ae45ad143,
title = "Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus",
abstract = "Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.",
author = "Fangfang Dong and Dandan Li and Dan Wen and Suhua Li and Chaoyue Zhao and Yue Qi and Rohit Jangra and Cuiping Wu and Dequan Xia and Xing Zhang and Fei Deng and Kartik Chandran and Zhen Zou and Fei Yuan and Aihua Zheng",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41541-018-0096-y",
language = "English (US)",
volume = "4",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus

AU - Dong, Fangfang

AU - Li, Dandan

AU - Wen, Dan

AU - Li, Suhua

AU - Zhao, Chaoyue

AU - Qi, Yue

AU - Jangra, Rohit

AU - Wu, Cuiping

AU - Xia, Dequan

AU - Zhang, Xing

AU - Deng, Fei

AU - Chandran, Kartik

AU - Zou, Zhen

AU - Yuan, Fei

AU - Zheng, Aihua

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.

AB - Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.

UR - http://www.scopus.com/inward/record.url?scp=85060766898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060766898&partnerID=8YFLogxK

U2 - 10.1038/s41541-018-0096-y

DO - 10.1038/s41541-018-0096-y

M3 - Article

AN - SCOPUS:85060766898

VL - 4

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 5

ER -